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A b s t r a c t
Introduction: Intravenous thrombolysis is the treatment of choice in patients presenting with high- and intermedi-
ate-risk pulmonary embolism. The role of percutaneous mechanical pulmonary thrombectomy (PMPT) is not fully 
established, although selected patients can be managed with this method.
Aim: This open-label single-centre prospective pilot study was aimed at assessing the feasibility of PMPT for the 
treatment of severe pulmonary embolism in a Polish hospital. We also evaluated the safety and efficacy of such 
management.
Material and methods: We managed 7 patients, aged 52.7 ±16.6 years, presenting with high- and intermediate-risk 
pulmonary embolism (4 patients with class 5 and one patient with class 4 of the Pulmonary Embolism Severity 
Index), with occlusion of at least 2 lobar arteries and contraindications for thrombolysis. Percutaneous mechanical 
pulmonary thrombectomy was performed using the AngioJet system.
Results: It was possible to introduce the thrombectomy system to the pulmonary arteries in all patients. The pro-
cedure was successful in 6 patients (technical success rate: 85.7%). Two (28.6%) patients died during the hospital 
stay, one patient with unsuccessful thrombectomy and the other due to pneumonia. In all survivors control echo-
cardiography demonstrated normalised function of the right ventricle. Also, dyspnoea disappeared and blood gas 
parameters normalised. There was no recurrent thromboembolism during 3–14 months of follow-up.
Conclusions: In the Polish setting, in selected patients, management of high- and intermediate-risk pulmonary em-
bolism with PMPT is technically feasible. Such treatment is relatively safe and effective. It can be an alternative to 
standard management, especially in patients with contraindications for fibrinolysis or surgical embolectomy.
Key words: thromboembolic disease, pulmonary embolism, mechanical thrombectomy system, pulmonary artery.
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Introduction
Venous thromboembolic disease represents the 
third most common cause of cardiovascular death 
in the United States and Europe [1–3]. Symptomatic 
pulmonary embolism (PE) occurs in about 500,000 
patients annually, with an estimated mortality as 
high as 30% in high-risk patients [2, 3]. According 
to current guidelines, based on clinical and hae-
modynamic criteria and the risk of early mortality, 
severe PE can be categorised into two main groups 
[2–5]. The first one comprises high-risk PE, which 
clinically manifests with haemodynamic instability 
and systemic hypotension (systolic blood pressure 
< 90 mm Hg, pressure drop of more than 40 mm Hg 
or requiring administration of inotropic agents [5, 6]). 
In this form of PE imaging studies usually reveal 
a “saddle embolus” at the bifurcation of the pulmo-
nary trunk, embolism of the main pulmonary artery, 
or embolic occlusion of at least two lobar arteries 
[3–6]. Mortality in high-risk PE is at the level of 60%, 
and in 66% of these patients fatal outcomes take 
place during the first hours from the onset of clin-
ical symptoms [3–5]. The remaining patients with 
severe PE, those with intermediate risk of mortality, 
do not reveal hypotension, but present with clinical 
symptoms comprising dyspnoea and/or tachycardia. 
Laboratory diagnostics, ECG and imaging studies 
demonstrate in these patients significant overload 
of the right ventricle, severe blood gas disturbances 
and in some patients also markers of myocardial ne-
crosis. Estimated 30-day mortality in patients with 
intermediate risk PE is at the level of 15–20%, and 
these patients are at a risk of developing pulmonary 
hypertension and right ventricle heart failure [7–9].
Pulmonary embolism is primarily managed with 
anticoagulants and fibrinolytic agents, while surgical 
pulmonary embolectomy is performed in selected 
patients [5, 7–11]. Given the fact that as many as 
40% of patients with class 4 or 5 of the Pulmonary 
Embolism Severity Index (PESI) present with contra-
indications for both surgical embolectomy and fibri-
nolytic therapy, percutaneous mechanical pulmonary 
thrombectomy (PMPT) seems to be an attractive 
alternative treatment modality [6, 10, 12–17]. Re-
cently a number of studies on the use of PMPT for 
the management of PE in patients presenting with 
high or intermediate risk have been published. They 
primarily comprised open-label studies and retro-
spective analyses of the cohorts, but also a few pro-
spective trials. Still, to the best of our knowledge, 
a similar paper on Polish patients has not yet been 
published. 
Aim
This open-label study was aimed at assessing the 
feasibility of management of severe PE using PMPT 
in a  Polish hospital. We also evaluated the safety 
and efficacy of such treatment, with reference to the 
results of this treatment in other countries [6, 10, 
12–18]. 
Material and methods
In 2015 the University Hospital in Krakow initi-
ated a pilot programme of the management of pa-
tients presenting with high- and intermediate-risk 
PE, 4 or 5 class of PESI, dysfunction of the right 
ventricle, elevated troponin and contraindications 
for fibrinolytic therapy. Absolute contraindications 
for fibrinolysis comprised head trauma, brain sur-
gery and other major surgical procedures. Relative 
contraindications regarded patients with traumatic 
and surgical injuries associated with a high risk of 
uncontrollable bleeding, such as recent fracture or 
patients after cardiopulmonary resuscitation with 
injuries of the ribs and sternum, and patients with 
neurological pathologies that potentially could be 
exacerbated by bleeding to the nervous tissue, such 
as polyneuropathy. Although several endovascular 
techniques can be used for the purpose of mechan-
ical thrombectomy of the pulmonary arteries, con-
sidering the fact that our team has expertise in the 
use of the AngioJet (Boston Scientific, Natick, MA, 
USA) rheolytic thrombectomy system, we decided to 
use this endovascular device. For the purpose of this 
programme and also for everyday practice, we cre-
ated an algorithm – how to diagnose and manage 
PE patients, and which patients should be qualified 
for PMPT (Figure 1). The study protocol has been ap-
proved by the Bioethical Committee of the Regional 
Board of Physicians in Krakow (approval No138/KBL/
OIL/2015).
We primarily focused at the feasibility of PMPT, 
which was defined as the rate of technically success-
ful procedures, and at safety of such management 
measured by in-hospital mortality and prevalence of 
severe adverse events. We also performed an anal-
ysis of how PMPT improved haemodynamic, angio-
graphic and clinical parameters in these patients. 
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Analysed clinical criteria comprised improvement 
of function of the right ventricle, postprocedural 
adverse events and in-hospital mortality. Haemody-
namic and laboratory parameters, such as systolic 
blood pressure, heart rate and blood gases param-
eters (pH and O2 saturation) were evaluated before 
and after the procedure (Table I). Echocardiography 
was performed before endovascular thrombectomy, 
6–12 h after completion of PMPT and on the 2nd–4th 
postprocedural day. 
We prospectively evaluated results of the treat-
ment in 7 patients (4 women and 3 men) who were 
managed from December 2015 to April 2017. Pa-
tients were aged 52.7 ±16.6 years. All of them pre-
sented with high or intermediate risk PE, and the 
diagnosis was confirmed by computed tomography 
(CT) angiography (Tables II and III). There were also 
4 patients who met the above-described criteria but 
for different reasons were not managed with PMPT 
(Figure 2). Out of these patients, 3 of them improved 
clinically during preparation for the procedure and 
no longer presented with a  high risk class accord-
ing to the PESI. Another patient, with a long history 
of PE and haemodynamic instability, was managed 
with thrombolysis instead of PMPT, since consider-
ing the duration of the embolism and poor clinical 
status of this individual, the endovascular approach 
seemed technically challenging and very risky. 
According to our protocol (Figure 1), patients 
presenting with high- or intermediate-risk PE, 4 and 
5 classes PESI, with occlusion of at least 2 lobar ar-
teries and contraindications for thrombolysis were 
managed with PMPT. Other patients received stan-
dard treatment using thrombolysis or antithrom-
1 – primary or absolute/relative contraindications for fibrinolysis, 2 – PESI – Pulmonary Embolism Severity Index, 3 – AngioJetTM rheolitic thrombectomy, 
4 – no patients consent, no vascular access, 5 – no clinical improvement: hypotension, hypoxemia, 6 – AngioJetTM rheolitic thrombectomy + local administra-
tion of alteplase.
Pulmonary embolism (PE)
Systemic intravenous alteplase Intermediate risk PE
PESI(2) class 1–3
Standard anticoagulations
AngioJet(3) or mechanical thrombectomy  
+ thrombolysis(6)
Yes
(1)
(5)
No
High risk PE (systolic blood pressure < 90 mm Hg or drop  
of pressure ≥ 40 mm Hg longer than 15 min)
Figure 1. Algorithm of management of patients with pulmonary embolism in our hospital
Confirmation Yes No
Clinical
Echocardiography
Pulmonary CT 
angiography
PESI(2) class 4–5, echo (+), troponin (+)
(4)
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botic agents. Out of these 7 patients managed with 
PMPT, there was one presenting with PESI class 4 
and 4 patients with PESI class 5. Four patients pro-
vided their written informed consent to undergo 
the procedure, while the remaining 3 patients were 
unconscious and thrombectomy was performed as 
a  life-saving intervention. Three patients required 
mechanical ventilation before and during the en-
dovascular procedure. There were cardiac arrests 
in 2 patients before the procedure and in 1 patient 
during the procedure. 
All patients managed with PMPT were admin-
istered therapeutic doses of low-molecular-weight 
heparin once PE has been suspected. In the case of 
relative contraindications for anticoagulation (there 
was 1 patient after head trauma and 2 patients after 
abdominal surgery) patients received subtherapeu-
tic doses of heparin. In addition, in 2 patients with 
contraindications for therapeutic anticoagulation 
we implanted retrievable cava filters. After PMPT 
patients were managed in the intensive care unit. 
Once their clinical status became stable, which oc-
curred on the 3rd–13th postprocedural day, they were 
transferred to the internal medicine ward and after 
further stabilisation of their status they were dis-
charged home, with the recommendation of long-
term oral anticoagulation. 
Endovascular technique
In this group of patients we did not use mechan-
ical thrombectomy augmented by local fibrinolysis, 
which was an option in our protocol (Figure 1). En-
dovascular thrombectomy was performed 3–20 h 
from the onset of symptoms of PE (Table III). Femoral 
access was the preferred route for this intervention. 
This vein was cannulated with a 5 Fr or 6 Fr introduc-
er sheath. Then, over a  standard (such as InQwire 
Guide Wire, Merit Medical Systems) or hydrophilic 
(for example, AqWire, Covidien, ev3 Endovascular, 
Inc., Plymouth, MN, USA) guide wire, a  pigtail di-
agnostic catheter was positioned in the pulmonary 
trunk. This diagnostic catheter was then advanced 
into each pulmonary artery and angiography was 
performed. Routinely we used 10 ml of contrast on 
each side, or 30 ml in the case of injection of con-
trast at the level of the pulmonary trunk. This vol-
ume was adjusted depending on the clinical status 
of the patient and the value of the pulmonary pres-
sure. In the case of poor clinical status of the patient 
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and/or echocardiographic features of right ventricle 
overload, we tried to reduce the volume of contrast 
to 8–10 ml. After confirmation of embolisation, the 
above-described introducer sheath was replaced 
with a bigger one (6 Fr or 7 Fr). We suggest using 
the SiteSeer Judkins Right catheter (Medtronic, Min-
neapolis, MN, USA) or a  long sheath with a special 
tip, such as the 6 Fr 90 cm length Destination Guid-
ing Sheath (Terumo, Tokyo, Japan). Then the Angio-
Jet system was introduced. Using this device emboli 
were subsequently aspired from all occluded pulmo-
nary branches. Initially we performed 2–5 passages 
of the thrombectomy device in the occluded artery, 
with simultaneous assessment of the tolerance of 
the intervention by the patient. Then we evaluat-
ed the degree of residual stenosis in angiography. 
Of note, we did not perform embolectomy of small 
branches of the pulmonary artery, since navigation 
through these tiny vessels is associated with very 
high risk of haemorrhage. We also avoided aspira-
tions of embolic material lasting longer than 7–10 s, 
since such manoeuvres can result in dyspnoea and 
cardiac decompensation. Thrombectomy was con-
tinued until all major branches of the pulmonary 
arteries became recanalised, or the patient signifi-
cantly improved clinically in terms of haemodynam-
Table II. Demographic, clinical and diagnostic 
data of all treated patients (n = 7)
Parameter Value
Gender: 
Males 3 (43%)
Females 4 (57%)
Age, mean ± SD [years] 52.7 ±16.6
Risk factors for PE:
Immobilisation 2 (29%)
Recent surgery 2 (29%)
Malignancy 1 (14%)
Recent trauma 1 (14%)
Obesity 1 (14%)
Contraindications for thrombolysis 7 (100%)
Symptoms:
Dyspnoea 7 (100%)
Chest pain 4 (57%)
Presyncope/syncope 3 (43%)
Cardiac arrest 2 (29%)
Palpitations 2 (29%)
Clinical presentation:
Intermediate-risk pulmonary embolism: 5 (71%)
PESI class 5 4 (57%)
PESI class 4 1 (14%)
High-risk pulmonary embolism + shock 2 (43%)
Hypoxia 7 (100%)
Tachycardia (heart rate > 130/min) 7 (100%)
Diagnostic modalities:
Right heart strain 7 (100%)
Right ventricular dilatation 6 (86%)
Troponin I > 0.01 ng/ml 6 (86%)
Right ventricle failure (echocardiography) 7 (100%)
Paradoxical motion of interventricular septum 2 (29%)
Embolism of both pulmonary arteries in CT 
angiography
1 (14%)
More than 2 lobar arteries occluded in CT 
angiography
7 (100%)
Deep vein thrombosis of the lower extremities 
demonstrated by sonographic examination
2 (29%)
11 patients met criteria for mechanical 
thrombectomy
7 patients managed with mechanical 
thrombectomy:
– 2 patients with high-risk PE
– 5 patients with intermediate-risk PE
Successful thrombectomy: 6 patients
1 patient died on day 7 due  
to pneumonia
Successful final outcome 5 patients
4 patients excluded: 
– 2 patients – low risk PE
–  1 patient – intermediate risk PE, PESI  
3 class, active bleeding after  
nephrectomy
–  1 patient – long history of PE, deep  
vein thrombosis, cardiac arrest, finally 
managed with systemic fibrynolisis
1 patient – intraprocedural cardiac arrest, 
thrombectomy unsuccessful, death
Figure 2. Flow chart of patients
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ic stability and blood gas parameters, even if the 
angiographic result was suboptimal. We regarded 
a 30% residual stenosis as acceptable on condition 
that there was good inflow to peripheral branches of 
the pulmonary arteries. Also 30–50% stenosis with 
significant improvement of clinical status (normali-
sation of heart rate and blood gas parameters) and 
good inflow to peripheral branches was interpreted 
as a good result. Residual stenosis more than 50% or 
no clinical improvement represented an indication 
for more passages of the thrombectomy system with 
subsequent angiographic control. In this patient se-
ries in each individual we performed 3–6 aspirations 
with the AngioJet system. Duration of the procedure 
ranged from 30 to 70 min and the total volume of 
contrast injected ranged from 50 to 100 ml.
Statistical analysis
Statistical analysis was performed using the Sig-
maStat for Mac, Version 7.0 software (SPSS Inc., Chi-
cago, IL, USA). Continuous variables were expressed as 
medians, categorical data as numbers and percentages.
Results 
Diagnosis of PE was made based on the results 
of pulmonary CT angiography. CT angiography in 
1 patient revealed an occlusion of both pulmonary 
arteries, in 5 patients occlusion of three lobar arter-
ies and in 1 patient occlusion of five lobar arteries 
(Table I). The Miller index (an angiographic measure 
of pulmonary occlusion, which is calculated as the 
sum of obstruction and perfusion indexes, rang-
ing from 0 = best to 34 = worst) scored 16–33 (Ta-
ble I). In addition, in all patients echocardiography 
demonstrated signs of right ventricle overload, such 
as dilatation of the right ventricle (7 patients) and 
abnormal mobility of the interventricular septum 
(3 patients).
In total, 2 patients died during the hospital stay, 
1 patient with intraprocedural cardiac arrest and un-
successful thrombectomy (mentioned above), and 
another patient who died 7 days after the procedure 
due to pneumonia. Thus, the in-hospital mortali-
ty was 28.6%. Except for 1 case of intraprocedural 
death and 1 case of fatal pneumonia, there were 
no serious adverse events directly associated with 
PMPT, such as perforation of the pulmonary artery or 
another blood vessel, distal embolisation or bleeding 
from the access site. In 3 individuals, who were our 
first patients managed with PMPT, there were brad-
yarrhythmias during a  longer aspiration of embolic 
material. These symptoms ceased spontaneously 
with discontinuation of aspiration; thus we consider 
these adverse events as moderate ones. Based on 
these experiences we limited the time of aspiration 
to 7–10 s, and bradyarrhythmias were not seen in 
subsequent patients. 
It was possible to introduce the AngioJet sys-
tem to pulmonary arteries in all patients. Mechan-
ical thrombectomy with this device was successful 
in 6 patients (technical success rate – 85.7%). The 
only patient with unsuccessful thrombectomy died 
during the procedure.
Five PMPT procedures were successful (exam-
ple results of thrombectomy – Photos 1 and 2). In 
these patients normalisation of heart rate took place 
during the first 2 h after the procedure, while the 
improvement of respiratory function manifesting 
with disappearance of dyspnoea and normalisa-
tion of blood gas parameters occurred 2–6 h after 
thrombectomy. Only 1 patient, with a recent history 
of myocardial infarction, required a 3-days long in-
fusion of dopamine. The remaining 4 patients were 
haemodynamically stable just after the procedure. 
Control echocardiography in all survivors demon-
strated normalised function of the right ventricle.
Duration of hospital stay in survivors was 6–20 
days. There were no recurrent thromboembolic events 
during 3–14 months of follow-up. Changes of angio-
graphic and laboratory parameters after thrombecto-
my are summarised in Table I. 
Discussion
The results of our case series suggest that PMPT 
can be seen as an alternative to standard manage-
ment, especially in patients with contraindications 
for fibrinolysis or surgical embolectomy. A  small 
sample size, single-centre study and no control 
group are the main limitations of this survey. On the 
other hand, a standardised protocol for PMPT seems 
to be a strong point of our report.
Early aggressive treatment restoring patency of 
occluded pulmonary arteries represents the princi-
pal factor affecting mortality in severe PE [2]. Ac-
cording to the guidelines of the European Society 
of Cardiology, shock or systemic hypotension is an 
accepted indication for urgent thrombolysis in pa-
tients with acute PE [2, 7]. Surgical or endovascular 
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Photo 1. Result of thrombectomy in patient with right-sided pulmonary embolism: A – initial image – oc-
clusion of the middle and inferior lobar arteries, and also partial occlusion of the superior lobar artery,  
B – AngioJet system introduced to the pulmonary artery, C – final result
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thrombectomy can be an option in selected cases 
[10, 12–17]. Although intravenous systemic throm-
bolysis is recommended as a life-saving treatment in 
severe PE, the clinical benefit of such management 
is not obvious. According to the ICOPER registry, sys-
temic fibrinolysis did not affect mortality in patients 
presenting with high-risk PE [3]. The American Col-
lege of Chest Physicians recommends an endovas-
cular intervention only in patients with contraindi-
cations for fibrinolysis, primarily those with a high 
risk of bleeding [19], while the European Society of 
Cardiology suggests the endovascular approach as 
an alternative for surgical embolectomy in patients 
with unsuccessful thrombolysis [7]. Still, a  number 
of single-centre studies, as well as meta-analyses of 
such trials, have demonstrated that PMPT in high- or 
intermediate risk-PE can be safe and effective, and 
that the risk of serious adverse events is comparable 
or even lower than that after fibrinolytic therapy [6, 
10, 12–17]. This relatively high efficacy of PMPT is 
related to the fact that mechanical fragmentation of 
the embolus increases the chance of recanalisation 
of the pulmonary artery. In addition, the dose of fi-
brinolytic agent that is directly administered to the 
pulmonary arteries is reduced and therefore bleed-
ing complications are less frequent [3, 6, 14–16]. 
Consequently, in some highly experienced centres 
PMPT is regarded as the procedure of choice, even 
if systemic thrombolysis and surgical embolectomy 
still play important roles [6, 10, 13–17]. It has been 
emphasized that clinical success of PMPT is primari-
ly associated with recanalisation of pulmonary and/
or lobar arteries. This in line with our observations. 
In our material intraprocedural death occurred in 
a  patient with unsuccessful thrombectomy of the 
pulmonary arteries. Also, following observations 
of other researchers who demonstrated that the 
decision upon completion of the procedure should 
be based on the clinical and not angiographic out-
come, we finished PMPT once the patient clinically 
improved, irrespective of the angiographic picture 
of the pulmonary circulation. Such a strategy is due 
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Photo 2. Result of thrombectomy in patient with bilateral occlusion of pulmonary arteries: A – initial image: 
occlusion of the left superior and inferior lobar arteries, B – after thrombectomy of the inferior lobar arteries 
of the left lung, C – occlusion of the superior, middle and inferior lobar arteries of the right lung, D – recan-
alisation of the inferior, E – superior lobar arteries
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to the fact that thrombectomy of distal pulmonary 
vessels is associated with especially high risk of 
life-threatening technical failures [6, 10, 15].
The question whether PMPT should be followed 
by local pharmacological thrombolysis is also under 
debate. Lee et al. reported the results of such man-
agement in 91 patients presenting with intermediate 
risk PE. They administered alteplase, with mean time 
of drug infusion 18 h, and observed clinical improve-
ments in all patients [20]. This observation suggests 
that low-dose local thrombolysis can be an effective 
additional treatment in patients without contraindica-
tions for fibrinolytics. There were published two stud-
ies assessing long-term local fibrinolysis using the 
EkoSonic Endovascular System [21, 22]. The system 
has been found effective in patients presenting with 
intermediate-risk acute PE and the results were supe-
rior to standard anticoagulation with heparin. In the 
first study the authors used 10–20 mg of alteplase, 
while in the other the total dose of alteplase was 
24 mg. Consequently, there were significantly different 
rates of hemorrhagic adverse events (0% vs. 10%). It 
should also be emphasized that in the first study [21] 
84% of patients did not meet the inclusion criteria; 
thus the group assessed was very highly selected.
Bradyarrhythmia associated with longer aspira-
tions of embolic material is a well-known problem. 
This complication was seen in 15% of patients man-
aged by some authors [23–25], while others did not 
report these adverse events [6, 10]. Short aspira-
tions seem to be the best measure to avoid these 
complications. In is not clear which factors trigger 
bradyarrhythmias. Some authors blamed haemo-
lysis-related hyperkalaemia, adenosine or a  spasm 
of arteries caused by nitric oxide sequestrated in 
the pulmonary circulation [24, 25]. We did not use 
prophylaxis with aminophylline, which was recom-
mended by some authors [25]. Also, in our patients 
management of bradyarrhythmias with endocavi-
tary stimulation was not needed. 
Some authors reported quite a high rate of serious 
adverse events associated with the use of the AngioJet 
system, such as haemoptysis, renal failure, peripheral 
embolisation and bradyarrhythmias [23]. Still others 
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found this endovascular device to be rather safe [6, 
10]. In our patients, except for bradyarrhythmias, there 
were no serious complications, and even those could 
be avoided after modification of the procedure.
Conclusions
The results of treatment of our patient series, 
even respecting the fact that this was a small group, 
demonstrates that in the Polish context PMPT of 
high- or intermediate-risk PE is technically feasible, 
and such management is relatively safe and effective. 
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